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The cellular immunogenicity of formulated plasmid DNA and replication-defective human adenovirus
serotype 5 (Ad5) vaccine vectors expressing a codon-optimized human immunodeficiency virus type 1 gag gene
was examined in baboons. The Ad5 vaccine was capable of inducing consistently strong, long-lived CD8-
biased T-cell responses and in vitro cytotoxic activities. The DNA vaccine-elicited immune responses were
weaker than those elicited by the Ad5 vaccine and highly variable; formulation with chemical adjuvants led to
moderate increases in the levels of Gag-specific T cells. Increasing the DNA-primed responses with booster
doses of either Ad5 or modified vaccinia virus Ankara vaccines suggests a difference in the relative levels of
cytotoxic and helper responses. The implications of these results are discussed.
Virus-specific cellular immunity, particularly that associated
with CD3 CD8 cytotoxic T lymphocytes (CTLs) (6, 15, 23–
25, 27), has been increasingly recognized to have an important
role in controlling persistent human immunodeficiency virus
type 1 (HIV-1) infection. Recently, we reported on the efficacy
of using CRL1005 adjuvant-formulated DNA and recombinant
adenovirus type 5 (Ad5) vectors that express simian immuno-
deficiency virus SIVmac239 gag to protect rhesus macaques
(Macaca mulatta) against disease progression from a patho-
genic infection with simian-human immunodeficiency virus
SHIV89.6P (25). In developing a vaccine against HIV-1, it is
important to evaluate the cellular immunogenicity of equiva-
lent vectors expressing HIV-1 gag in nonhuman primates. The
most commonly used rhesus macaques weigh considerably less
(3 to 12 kg) than human adults. In contrast, adult baboons
(genus Papio) are nearly half the size of adult humans. They
can be infected with several simian-human immunodeficiency
virus strains (1, 14) and have been shown to develop AIDS-like
disease symptoms when infected with HIV-2 (5). They thus
provide a suitable alternative immunological model that may
closely approximate vaccine-induced immune responses in hu-
mans. Prior to this work, vaccine testing in baboons (4, 9, 13,
17, 26) had largely involved candidates aimed at generating
virus-specific neutralizing antibodies. Hence, techniques for
quantitative analyses of antigen-specific T-cell responses in this
primate system were limited.
In this study, we evaluated the cellular immune responses
induced in adult baboons by using several vector approaches
for treatment of HIV-1. A DNA vaccine was constructed by
inserting a synthetic gene for HIV-1 CAM1 gag, which used
human-biased codons (16), into the V1Jns plasmid under the
control of the human cytomegalovirus-human intron A pro-
moter and bovine growth hormone terminator (8, 25). The
Ad5 vaccine construct is a prototypic vector containing an E1
deletion replaced with the expression cassette for the same
codon-optimized gag gene. Methods for constructing and char-
acterizing such vectors have been described earlier (25). The
modified vaccinia virus Ankara (MVA) vector was constructed
by inserting the same gag gene into the PmeI site of the pLW22
shuttle vector (20). gag was placed under the control of a
synthetic early-late vaccinia virus promoter and was inserted
into the site of deletion II in the MVA genome by homologous
recombination. The generation of the vaccine in chicken em-
bryo fibroblasts and the characterization of the recombinant
MVA virus have been described elsewhere (20).
Groups of three baboons (Papio cynocephalus; 25 to 34 kg
each) were given priming immunizations with (i) 5 mg of
V1Jns–HIV-1 gag (the DNA vaccine) in phosphate-buffered
saline, (ii) 5 mg of the DNA vaccine formulated with 700 g of
aluminum phosphate (HCI Biosector, Frederikssund, Den-
mark), (iii) 5 mg of the DNA vaccine formulated with 7.5 mg
of the adjuvant CRL1005 (CytRx Corp., Atlanta, Ga.) and 0.75
mM benzyalkonium chloride (Spectrum, Gardena, Calif.), or
(iv) 1011 viral particles (VP) of replication-incompetent Ad5–
HIV-1 gag (the Ad5 vaccine). Each vaccine was prepared in a
1-ml volume and injected at a single site in the deltoid muscle
of an anesthetized animal by using a tuberculin syringe. In
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addition to intramuscular (i.m.) immunization, Ad5–HIV-1 gag
was also injected subcutaneously at four proximal sites (250 l
per site) above the deltoid muscle area. Table 1 details the
priming and booster immunizations that each baboon received.
All animal care and treatment were performed in accordance
with standards approved by the Institutional Animal Care and
Use Committee.
The levels of Gag-specific T cells (Fig. 1) from peripheral
blood mononuclear cell (PBMC) preparations were quantified
by the enzyme-linked immunospot (ELISPOT) assay by using
the same reagent sets described elsewhere (2). All antigen-
specific stimulation reactions were achieved by using a pool of
20-amino-acid (aa) peptides that overlapped by 10 aa and that
encompassed the entire Gag product sequence (SynPep, Dub-
lin, Calif.). The length of each peptide is inclusive to allow
detection of both CD4- and CD8-T-cell determinants.
Priming immunizations with 1011 VP of the Ad5–HIV-1 gag
vector induced in all six vaccinees high levels of Gag-specific T
cells which peaked at levels ranging from 530 to 2,050 spot-
forming T cells (SFC)/106 PBMCs at weeks 8 to 12 (Fig. 1).
FIG. 1. Levels of Gag-specific T cells in baboons immunized with DNA and viral vaccine vectors as a function of time (T). For the ELISPOT
assay, 2  105 to 4  105 PBMCs were plated on each well and the wells were incubated in the absence or presence of peptides at a 4-g/ml
concentration per peptide. The plotted values are differences in the numbers of IFN- SFC per 106 PBMCs for a given sample mixed with the Gag
peptide pool and the blank control. The average blank control count was about 18 SFC/106 PBMCs with a standard deviation of 28 SFC/106
PBMCs. Arrowheads indicate the times of immunization with the vectors described in each panel. The DNA-, DNA-aluminum phosphate (Alum)-,
and DNA-CRL1005-vaccinated animals received booster doses of either 108 VP of Ad5 or 109 PFU of MVA–HIV-1 gag vector at week 24.
TABLE 1. Immunization schedule and vaccines useda
Animals Priming immunization Booster at wk 24b
11017, 11361, 14232 1011 VP of Ad5 at wk 0 and 4 (i.m.) 1011 VP of Ad5 (i.m.)
10041, 11039, 11096 1011 VP of Ad5 at wk 0 and 4 (s.c.) 1011 VP of Ad5 (s.c.)
10432, 8698, 10875 None 108 VP of Ad5 (i.m.)
9895, 11251, 14811 DNA at wk 0, 4, and 8 (i.m.) 108 VP of Ad5 (i.m.)
8988, 9783, 10843 DNA-alum at wk 0, 4, and 8 (i.m.) 108 VP of Ad5 (i.m.), 109 PFU of MVA (i.m.), —c
10544, 11247, 11876 DNA-CRL1005 at wk 0, 4, and 8 (i.m.) 109 PFU of MVA (i.m.), 109 PFU of MVA (i.m.), 108 VP of Ad5 (i.m.)
11029 (naı̈ve) None None
a s.c., subcutaneously; Ad5, Ad5–HIV-1 gag; MVA, MVA–HIV-1 gag; DNA, 5 mg of V1Jns–HIV-1 gag; alum, 700 g of aluminum phosphate; CRL1005, 7.5 mg of
CRL1005 with 0.75 mM benzyalkonium chloride.
b For the group in which a different booster vaccine is given to each animal, the order of booster vaccines listed corresponds to that of animals listed in the first
column.
c This animal died of an unrelated cause after week 12.
7664 NOTES J. VIROL.
 on M









The magnitude of these responses was independent of the
route of administration. Immunization of the Ad5 vaccinees
with a third dose of the virus resulted in improved levels of
circulating Gag-specific T cells (1.3- to 4-fold and 2- to 10-fold
higher than the prebooster peak and set point levels, respec-
tively). The anti-Ad5 neutralizing antibody titers were deter-
mined by testing serially diluted serum samples for the ability
to block the expression of human secreted alkaline phospha-
tase from cells infected with an Ad5-human secreted alkaline
phosphatase vector; the titers for the Ad5 vaccinees ranged
from 139 to 4,000 at week 24. Animals 11017 and 11039
showed the lowest neutralizing antibody titers (139 and 201,
respectively) and the largest absolute increases in T-cell re-
sponses. The fact that the immune responses were increased
despite high levels of vector-specific neutralizing immunity
suggests that only a small amount of the Ad5 vaccine was
necessary to effect a significant expansion of the existing T-cell
pool.
Baboons immunized with the DNA vaccine alone developed
low levels of antigen-specific T cells following the priming
immunizations (138 SFC/106 PBMCs) (Fig. 1). The re-
sponses (293 to 705 SFC per 106 PBMCs at week 12) were
improved by combining the DNA vaccine with aluminum phos-
phate. One animal in the DNA-aluminum phosphate-vacci-
nated group (animal 10843) died due to an unrelated cause
during the course of the priming regimen. In the cohort vac-
cinated with DNA formulated with CRL1005 adjuvant, the
levels of circulating Gag-specific T cells were not significantly
higher than those in the DNA-alone control group in this
animal model system. The animals that received DNA-alone
vaccines were given a low (108 VP) booster dose of Ad5–
HIV-1 gag at week 24. The low Ad5–HIV-1 gag booster dose is
designed to simulate a case in which the subject has a preex-
isting Ad5-specific immunity capable of 99.9% neutralization
of a 1011-VP dose. Each of three baboons in a control group
was inoculated i.m. with a single dose of 108 VP of the Ad5
vaccine (booster control group) at the same time that the other
baboons received the booster immunization. The levels of
Gag-specific T cells in the DNA-alone vaccinees following the
booster dose increased to 200 to 1,500 SFC/106 cells. These
levels were comparable to those in the booster control group,
suggesting that the DNA immunizations did not significantly
prime for HIV-1 T-cell responses.
Several studies have shown that optimal HIV-1-specific T-
cell responses are obtained by administering boosters of re-
combinant poxvirus vaccines such as the MVA vaccine to
FIG. 2. 51Cr release assay of CTL killing by baboon effector cells of autologous target BLCLs that either were unpulsed (open circles) or were
pulsed with a pool of 20-mer peptides derived from HIV-1 Gag (closed circles). Effector cells were prepared from PBMCs that were collected at
week 36 (12 weeks after the booster dose) and were restimulated with a vaccinia virus expressing HIV-1 gag for 2 weeks. The percentages of specific
lysis were recorded at effector-to-target cell ratios (E:T) ranging from 40 to 5. In all cases, the spontaneous lysis did not exceed 15% of the
maximum 51Cr release values. Adj, adjuvant; sc, subcutaneous.
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animals receiving DNA priming immunizations (3, 11). We
decided that the remaining five DNA-adjuvant vaccinees were
best utilized by comparing the booster effects of the Ad5 vac-
cine with those of the MVA vaccine (Table 1). Gag-specific
responses in all DNA-adjuvant vaccinees were augmented by
immunization with either viral booster at week 24 (Fig. 1). The
two animals receiving DNA-adjuvant priming and Ad5 booster
immunizations (animals 8988 and 11876) developed peak T-
cell responses in the range of 1,800 to 2,500 SFC/106 cells,
which were markedly higher than those of the booster control
group animals. Animals that received the MVA booster like-
wise showed high postbooster T-cell levels (200 to 1,500 SFC/
106 cells), but these levels were slightly lower than those ob-
served in animals from the same DNA-adjuvant groups that
were given the Ad5 booster. A control cohort for the MVA
booster was not included in this study. However, immunization
of rhesus macaques with the same MVA–HIV-1 gag vector
resulted in consistently weak Gag-specific T-cell responses
(150 SFC/106 PBMCs) (7).
Cytotoxic functions of the vaccine-induced T-cell responses
(Fig. 2) were examined by in vitro killing of autologous B-
lymphoid cell lines (BLCLs) pulsed with the 20-aa peptide
pool by using established protocols (10). At week 36, all ani-
mals (with the exception of animal 11251) that received at least
a single injection of the Ad5 vaccine exhibited consistently
strong CTL activity (40% at an effector-to-target cell ratio of
40:1). Prior to the booster doses, none of the DNA vaccinees
showed any Gag-specific cytotoxic activity above that of the
unpulsed BLCL controls (data not shown). All three animals
that received MVA boosters at week 24 exhibited much weaker
CTL killing efficiencies than those of the DNA vaccinees that
received Ad5 boosters (Fig. 2).
The intracellular cytokine staining method (ICS) has been
widely utilized to distinguish the relative contributions of
CD4 and CD8 cells to the overall T-cell responses (18). We
have identified suitable commercial antibodies for staining
markers (CD3, CD16, CD4, CD8, and gamma interferon [IFN-
]) on baboon PBMCs. Anti-CD3 or anti-CD16 monoclonal
antibodies can be used interchangeably in order to exclude
cytokine-producing CD8 NK cells (CD3 CD16) (19). At
week 28, all six Ad5–HIV-1 gag vaccinees showed detectable
levels of effector CD8 T cells mixed with lower amounts of
CD4 T cells (range of anti-Gag CD8:CD4 cell ratios, 1.4:1
to 10:1) (Table 2; Fig. 3) following overnight restimulation with
the 20-aa peptide pool. Prior to any viral boost, all DNA
vaccinees exhibited largely CD4 antigen-specific IFN--pro-
ducing cells (0.14% of CD16 T cells) (data not shown).
The types of responses in the adjuvant-formulated-DNA
vaccinees after booster vaccinations with either the Ad5 or the
MVA vector were also compared. Two of the three animals
that received MVA–HIV-1 gag boosters exhibited responses
with a stronger CD4 component than a CD8 component
(CD4:CD8 cell ratios of 6:1 and 10:1 for animals 9783 and
10544, respectively) (Fig. 3); in the third animal, the overall
response was much weaker, which was consistent with the
ELISPOT assay results. It should be noted that the CD4 and
CD8 distributions were similar when either a 15-mer peptide
pool (with 11-aa overlaps) or a 20-mer peptide pool was used
for stimulation (data not shown). In contrast, the two animals
that received the Ad5 booster dose developed CD8-biased
T-cell responses (antigen-specific CD8:CD4 ratios of 2:1
and 8:1, respectively). This trend was likewise observed in
rhesus macaques immunized with a heterologous DNA-
CRL1005–Ad5 priming-booster regimen (7).
HIV-1-specific cellular responses in all vaccinees were as-
sessed at week 52, or about 7 months after the final immuni-
zation. All animals maintained levels of Gag-specific effector T
cells to within 30 to 80% of the postbooster peak levels. The
antigen-specific T-cell counts were consistently higher than
those at the set point (week 24) after the priming series, sug-
gesting an immunological benefit of the booster treatment.
The successful development of an HIV-1 vaccine for either
prophylactic or therapeutic application will require gene deliv-
ery systems that are potent and consistent in their ability to
elicit effective cellular immune responses. Herein, we provide
evidence that a nonreplicating human adenovirus vector is
capable of inducing consistently strong and stable HIV-1-spe-
cific cytotoxic T-cell responses in a large nonhuman primate
system. First, 10 out of the 11 baboons that received immuni-
zations of the Ad5–HIV-1 gag vaccine one or more times dur-
ing the study produced high levels of Gag-specific T cells (0.01
to 0.25% of lymphocytes) that were sustained for at least sev-
eral months. Second, the majority of the Gag-specific cellular
immune responses consistently originated from CD8 T cells,
a finding which is in agreement with the observed high effi-
ciencies of in vitro killing by vaccinee PBMCs of peptide-
pulsed autologous cell lines. Third, the virus is effective with
even a single low-dose immunization of 108 VP.
One limitation of viral vaccine vectors such as Ad5 or MVA
involves the negative effect of preexisting vector-specific im-
TABLE 2. Percentages of CD16 T lymphocytes that are Gag-
specific CD8 or CD4 cells in vaccinated animalsa
Vaccine (route)
Animal
% CD16 T cells
that wereb:
Priming Booster CD4 CD8
Ad5 Ad5 11017 0.17 1.84
11361 0.10 0.25
14232 0.06 0.52
Ad5 (s.c.) Ad5 (s.c.) 10041 0.10 0.14
11039 0.09 0.73
11096 0.06 0.18
None Ad5 8698 0.01 0.51
10875 0.02 0.06
10432 0.04 0.20
DNA Ad5 9895 0.07 0.03
11251 0.05 0.02
14811 0.05 0.38
DNA-alum Ad5 8988 0.07 0.56
DNA-CRL1005 Ad5 11876 0.26 0.67
DNA-alum MVA 9783 0.35 0.02
DNA-CRL1005 MVA 10544 0.23 0.04
11247 0.02 0.01
a Data are based on IFN- ICS analyses of PBMCs collected at week 28
(4 weeks postbooster). s.c., subcutaneously; alum, aluminum phosphatase.
b Mock-subtracted values.
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munity on the induced immunity against the vaccine antigen.
This limitation can be circumvented by priming with a nonim-
munogenic vector system such as DNA and then following that
with a heterologous viral booster (7, 28). Here we provide
evidence suggesting that an effective priming vaccine using
adjuvant-formulated DNA combined with an Ad5 booster
can result in a T-cell immune response that approaches those
observed with multiple high doses of an Ad5-based vaccine.
Comparison of the immune responses of the adjuvant-for-
mulated-DNA vaccinees given an Ad5 or an MVA booster is
suggestive of differences in polarization in the phenotype of
the Gag-specific T cells. The Ad5 booster was particularly
potent in eliciting a CD8-biased T-cell response. In contrast,
none of the three animals that received the MVA vector
produced a CD8-biased Gag-specific immunity. It should be
noted that the numbers of animals tested were limited and that
these findings should be reinforced with studies of other non-
human primate systems as well as of other poxviruses (12, 21).
It has been suggested that potent CD8- and CD4-T-cell
responses are both critical in controlling an HIV infection (22,
29), yet the relative magnitude and the intrinsic quality of both
types of responses remain unclear. It would appear that such
immunological parameters can be controlled by the nature of
the vaccine modality. Ultimately, the potential of these vaccine
approaches can be assessed only with clinical trials involving
healthy and HIV-1-infected individuals.
We thank Bernard Moss and Vanessa Hirsch (National Institutes of
Health) for providing the MVA vectors.
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